Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the health effects of expanded hemodialysis in patients who regularly receive hemodialysis treatment. The main goal is to determine if expanded hemodialysis reduces the risk of death from any cause compared to conventional hemodialysis, which is the standard treatment for most patients. This large, randomized trial aims to provide clear evidence about the benefits of using newer hemodialysis filters that remove more large middle molecules from the blood. Participants will continue their regular hemodialysis treatments using either a super high-flux dialyzer called the Nipro Elisio HX expanded hemodialysis or a conventional high-flux dialyzer as currently prescribed in routine care. The trial includes 4,800 participants, with 1,200 receiving expanded hemodialysis and 3,600 receiving conventional hemodialysis. The study will follow participants for an average of 2.9 years to compare health outcomes between the two groups. During the study, participants will not have extra visits or tests beyond their usual dialysis sessions. Researchers will collect data using healthcare databases and medical record reviews at some locations. They will measure outcomes including all-cause mortality, hospitalizations related to cardiovascular issues and infections, causes of death, and kidney transplant status. Participants will be followed for an average of nearly three years after randomization to monitor these outcomes and assess the overall effects of the dialysis methods.
Actively Recruiting
Researchers are evaluating the effects of lowering blood phosphate levels in adults with end-stage kidney disease ESKD who are receiving dialysis. This trial compares intensive lowering of serum phosphate towards the normal level 1.50 mmolL with a more liberal target 2.0 to 2.5 mmolL to see if it reduces death or major cardiovascular events, and improves physical health and quality of life. The study is a large, international, randomized controlled trial sponsored by The University of Queensland. Participants will be randomly assigned to one of two groups one targeting a liberal serum phosphate level where phosphate-lowering medications are only prescribed if levels exceed 2.5 mmolL, and the other aiming for an intensive target with medications used to lower phosphate to normal levels. The choice and dose of phosphate binders will be decided by the treating physician and participant. The treatment period is expected to last up to five years. During the study, participants will be monitored for cardiovascular events, death, physical health, fatigue, quality of life, and patient satisfaction. Assessments include tracking the time to cardiovascular death or major cardiovascular events, all-cause death, and quality of life using the EQ5D-5L measure. Data will be collected throughout the treatment period, with safety and effectiveness evaluated over five years.
Actively Recruiting
Researchers are evaluating the impact of real-time audio-video telemedicine consultations with a neonatologist, called teleneonatology, on early health outcomes of at-risk newborns delivered in community hospitals. This study uses a stepped wedge cluster randomized design to compare early mortality, morbidity, and delivery room care between neonates receiving teleneonatology support and those receiving usual care. The trial is led by Mayo Clinic and focuses on newborns facing significant resuscitation needs shortly after birth. The study involves two groups one where at-risk neonates receive care from the community hospital team with telemedicine support from a neonatologist located at a regional neonatal intensive care unit, and a control group where neonates receive the hospitals usual care without telemedicine consultation. The telemedicine connection allows real-time, two-way audio and video communication during advanced neonatal resuscitations. The study includes neonates born preterm under 32 weeks or requiring advanced resuscitation interventions such as prolonged positive pressure ventilation, alternative airway placement, or chest compressions. Participants include clinicians attending newborn resuscitations and eligible neonates born at participating community hospitals. Researchers will monitor outcomes including mortality within 7 days, early neonatal morbidity, combined mortality and morbidity, and the highest level of resuscitation given in the delivery room within the first hour. The study tracks these outcomes to assess the effect of teleneonatology on newborn health during this critical early period. The total study duration extends through May 2029.